Search results
Showing 76 to 90 of 165 results for medication administration
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
Evidence-based recommendations on sacituzumab govetican (Trodelvy) for treating unresectable, triple-negative locally advanced or metastatic breast cancer in adults after 2 or more systemic therapies, at least 1 of which was for advanced disease.
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
NICE has developed a medtech innovation briefing (MIB) on the needle-free arterial non-injectable connector .
Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.
Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management (NG228)
This guideline covers diagnosing and treating an aneurysmal (caused by a ruptured aneurysm) subarachnoid haemorrhage and its complications. It provides recommendations to improve diagnosis and ensure that the most effective treatments are offered. It includes guidance on follow-up care and information for people (aged 16 and over) who have had an aneurysmal subarachnoid haemorrhage, their families and carers.
The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)
NICE has developed a Medtech Innovation Briefing (MIB) on the Airsonett temperature-controlled laminar airflow device for persistent allergic asthma
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.
Hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids (IPG704)
Evidence-based recommendations on hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids in adults. This involves cutting the fibroids into small pieces to remove them.
View recommendations for IPG704Show all sections
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)
Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.
Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.
Evidence-based recommendations on endometrial cryotherapy for menorrhagia (heavy periods). This involves using cold temperatures to freeze and destroy the lining of the womb.
View recommendations for IPG157Show all sections
Sections for IPG157
NICE has developed a medtech innovation briefing (MIB) on the Secca System for faecal incontinence
Laparoscopic removal of uterine fibroids with power morcellation (IPG703)
Evidence-based recommendations on laparoscopic removal of uterine fibroids with power morcellation in adults. This involves cutting the fibroids into small pieces to remove them.
View recommendations for IPG703Show all sections